Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer

Fox Chase Cancer Center

Overview

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining radiofrequency ablation with surgery in treating patients who have stage I or stage II non-small cell lung cancer.

OBJECTIVES: * Determine the acute effects of intraoperative radiofrequency tumor ablation (RFA) in patients with resectable non-small cell lung cancer. * Determine the treatment-related toxicity in patients treated with this therapy. * Determine the dimensions of the RFA lesion produced by the ablation procedure in these patients. OUTLINE: Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes for each tumor immediately followed by tumor resection. PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Lung Cancer

Interventions

conventional surgeryPROCEDURE

radiofrequency ablationPROCEDURE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Diagnosis of malignant non-small cell lung cancer (NSCLC) * Intraoperative needle biopsy confirmation allowed * Resectable disease (stage I or II) * All tissue to be treated by radiofrequency tumor ablation must be completely contained within boundaries of planned lung resection * Medically fit to undergo lung resection PATIENT CHARACTERISTICS: Age: * Over 18 Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Other: * Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior or concurrent biologic therapy Chemotherapy: * No prior or concurrent chemotherapy Endocrine therapy: * No prior or concurrent endocrine therapy Radiotherapy: * No prior or concurrent radiotherapy Surgery: * See Disease Characteristics Other: * No other prior therapy for NSCLC

Locations (1)

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.